Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

2020 Year in Review - Breast Cancer

Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.
In this real-world retrospective study, more patients in the ribociclib cohort compared with palbociclib and abemaciclib maintained starting doses and fewer patients decreased to 50% of the starting dose.
In addition to the significant benefit observed in the MONARCH 2 study across first- and second-line treatment, marked effects were observed in patients with less encouraging prognostic indicators.
Adding palbociclib to fulvestrant as first-line therapy improves 1-year progression-free survival in postmenopausal women with hormone receptor–positive, HER2-negative, endocrine-sensitive, advanced breast cancer.
Across the MONALEESA-2, -3, and -7 clinical trials, first-line treatment with endocrine therapy and ribociclib mitigated negative effects on quality of life, global health scores, pain, and emotional functioning.
While progression-free survival was similar, overall survival was better in CDK4/6 inhibitor combinations as first-line therapy followed by everolimus combinations and chemotherapy.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras in tortor interdum, iaculis risus sit amet, tempor mauris. Donec justo est, blandit eget nibh vel, volutpat vestibulum nibh. Praesent finibus faucibus metus, eu congue ipsum dignissim ac. Morbi volutpat molestie nibh, malesuada fringilla risus feugiat eget. Fusce at finibus nisl. Quisque laoreet arcu eu mauris sodales lobortis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras in tortor interdum, iaculis risus sit amet, tempor mauris. Donec justo est, blandit eget nibh vel, volutpat vestibulum nibh. Praesent finibus faucibus metus, eu congue ipsum dignissim ac. Morbi volutpat molestie nibh, malesuada fringilla risus feugiat eget. Fusce at finibus nisl. Quisque laoreet arcu eu mauris sodales lobortis.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras in tortor interdum, iaculis risus sit amet, tempor mauris. Donec justo est, blandit eget nibh vel, volutpat vestibulum nibh. Praesent finibus faucibus metus, eu congue ipsum dignissim ac. Morbi volutpat molestie nibh, malesuada fringilla risus feugiat eget. Fusce at finibus nisl. Quisque laoreet arcu eu mauris sodales lobortis.

Results 1 - 10 of 10